With a market cap of $52.7 billion, Corteva, Inc. (CTVA) is an agricultural company serving markets in North America, Latin America, Asia Pacific, Europe, the Middle East and Africa. The company operates through two main segments: Seed and Crop Protection, developing advanced seed genetics, traits, and crop protection products to help improve agricultural productivity and resilience.
Companies over $10 billion are typically labeled as “large-cap” stocks, and Corteva fits that criteria perfectly. It also provides herbicides, insecticides, nitrogen stabilizers, and digital agriculture solutions that help farmers improve crop yields and profitability.
Shares of the Indianapolis, Indiana-based company are down 3.9% from their 52-week high of $80.90. Shares of Corteva have risen 18.6% over the past three months, outpacing the Nasdaq Composite’s ($NASX) 4% decline over the same time frame.
CTVA stock is up 15.1% on a YTD basis, outperforming the NASX’s 2.3% decline. However, over the long term, shares of the agricultural technology company have returned 28.1% over the past 52 weeks, lagging behind the NASX’s 30% return over the same time frame.
The stock has been trading above its 50-day moving average since late November 2025.
Corteva shares rose marginally after Q4 results on Feb. 3, which were in line with Wall Street expectations for adjusted EPS of $0.22. The company also highlighted a strong full-year performance, reporting sales of $1.20 billion on revenue ($1.75 per share) of $17.40 billion, while operating cash flow rose 51% to $3.5 billion and free cash flow rose 69% to $2.9 billion.
Additionally, management maintained its outlook for operating EBITDA of $4 billion to $4.2 billion and operating EPS of $3.45 to $3.70, although quarterly revenue of $3.91 billion fell short of consensus estimates, supporting investor confidence.
In comparison, competitor CF Industries Holdings, Inc. (CF) has outperformed CTVA stock. Shares of CF Industries have grown 42% over the past 52 weeks and 41.6% on a YTD basis.
Despite the underperformance of CTVA stock over the past year, analysts are moderately optimistic about its prospects. The stock has a consensus rating of “average buy” from the 22 analysts covering the stock, and an average price target of $83.35 is a 7.3% premium to current levels.
As of the date of publication, Sohni Mondal had no position (either directly or indirectly) in any of the matters mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com
